Global Pathogen Analysis Service

GPAS is building analysis platforms that enable accurate detection and monitoring of infectious diseases, empowering an 'Always On' early warning system of potential outbreaks, and improve health outcomes for everyone, wherever they live.

Infectious Diseases and AMR are among the greatest challenges of our time

Climate change, rapid urbanisation, global travel, and changing land use are dramatically increasing the risk of emerging infectious diseases.

Between 2025 and 2050, 39 million lives are forecast to be lost to antimicrobial resistance (AMR)—equivalent to the population of Canada (source: University of Oxford).

Additionally, there is a 27.5% probability of a pandemic occurring within the next 10 years, putting millions of lives and trillions of dollars at risk (source: Airfinity).

GPAS is targeting the millions of lives lost through the inappropriate treatment of infectious diseases and the avoidable escalation from local outbreaks to pandemics.

Mycobacteria Pipeline

The Mycobacterium analysis includes species identification, lineage calling, identification of related isolates of Mycobacterium tuberculosis complexes and resistance prediction to 15 drugs. The pipeline can also analyse 190 non-tuberculous mycobacteria (NTMs).

Its features and advantages include: human read removal, the transformational speed of its complete analysis & alignment to the WHO V2 catalogue.

Supported NGS Technologies: Illumina and Oxford Nanopore Technologies (experimental)

Discover

SARS-CoV-2 Pipeline

The SARS-CoV-2 analysis includes consensus genome assembly, lineage assignment, and identification of related isolates, for SARS-CoV-2 sequenced using tiled amplicon sequencing.

Its features and benefits include human read removal, the transformational speed of its complete analysis & phylogenetic relatedness.

Supported Technologies: Illumina and Oxford Nanopore Technologies.

Discover